冠昊生物收盘下跌3.45%，滚动市盈率167.79倍，总市值46.80亿元

Core Insights - Guanhao Biological's stock closed at 17.65 yuan, down 3.45%, with a rolling PE ratio of 167.79 times and a total market value of 4.68 billion yuan [1] - The average PE ratio in the medical device industry is 55.76 times, with a median of 39.14 times, placing Guanhao Biological at the 113th position in the industry ranking [1] - On August 14, the net outflow of main funds for Guanhao Biological was 16.40 million yuan, with a total outflow of 71.66 million yuan over the past five days [1] Company Overview - Guanhao Biological focuses on developing new products and technologies with independent intellectual property rights, aiming to enhance product quality and optimize product structure [2] - The company operates three main business segments: biomaterials, pharmaceuticals, and cells, and is recognized as a "National Intellectual Property Advantage Enterprise" [2] - Key products include biological dura (spinal) membrane patches, sterile biological dressings, and corneal implants, among others [2] Financial Performance - In the first quarter of 2025, Guanhao Biological reported revenue of 94.80 million yuan, a year-on-year increase of 3.67%, and a net profit of 14.87 million yuan, also up 3.30% year-on-year, with a gross profit margin of 77.05% [2]